文献速递类风湿关节炎

工程化白细胞介素-10通过增强淋巴结转运抑制小鼠类风湿关节炎

Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models.
PubMed 文献 · Arthritis Rheumatol · 2021-03-08

本研究通过将白细胞介素-10(IL-10)与血清白蛋白(SA)融合表达SA-IL-10,在胶原抗体诱导关节炎和胶原诱导关节炎两种小鼠模型中评估其疗效。结果显示SA-IL-10较未修饰IL-10在淋巴结中蓄积增强,可恢复爪部免疫细胞组成、增加抑制性替代活化巨噬细胞频率、降低引流淋巴结IL-17A水平并保护关节形态,疗效与抗TNF抗体相似,且静脉、局部或皮下给药效果相当。

要点

  • SA-IL-10融合蛋白增强在淋巴结的蓄积,优于未修饰IL-10。
  • SA-IL-10恢复爪部免疫细胞组成并保护关节形态。
  • 静脉、局部或皮下给药SA-IL-10疗效相当,利于临床转化。

核心结论

  • SA融合是IL-10用于类风湿关节炎治疗的一种简单有效的工程化策略,具有临床转化潜力。

研究设计与样本

  • 重组表达SA融合IL-10(SA-IL-10),在胶原抗体诱导关节炎小鼠(每组n=4-7)和胶原诱导关节炎小鼠(每组n=9-15)中静脉注射野生型IL-10或SA-IL-10,评估淋巴结滞留、爪部免疫细胞组成及治疗效果。

主要发现

  • SA融合使IL-10在小鼠淋巴结的蓄积较未修饰IL-10增强。
  • 静脉SA-IL-10治疗使爪部免疫细胞组成恢复正常,提高抑制性替代活化巨噬细胞频率,降低爪引流淋巴结IL-17A水平,并保护关节形态。
  • 静脉SA-IL-10治疗疗效与抗肿瘤坏死因子抗体治疗相似。
  • SA-IL-10经静脉、局部或皮下给药时疗效相当。

临床怎么用

  • SA-IL-10在两种小鼠关节炎模型中显示疗效且多途径给药有效,支持进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) is a major autoimmune disease that causes synovitis and joint damage. Although clinical trials have been performed using interleukin-10 (IL-10), an antiinflammatory cytokine, as a potential treatment of RA, the therapeutic effects of IL-10 have been limited, potentially due to insufficient residence in lymphoid organs, where antigen recognition primarily occurs. This study was undertaken to engineer an IL-10-serum albumin (SA) fusion protein and evaluate its effects in 2 murine models of RA. METHODS: SA-fused IL-10 (SA-IL-10) was recombinantly expressed. Mice with collagen antibody-induced arthritis (n = 4-7 per group) or collagen-induced arthritis (n = 9-15 per group) were injected intravenously with wild-type IL-10 or SA-IL-10, and the retention of SA-IL-10 in the lymph nodes (LNs), immune cell composition in the paws, and therapeutic effect of SA-IL-10 on mice with arthritis were assessed. RESULTS: SA fusion to IL-10 led to enhanced accumulation in the mouse LNs compared with unmodified IL-10. Intravenous SA-IL-10 treatment restored immune cell composition in the paws to a normal status, elevated the frequency of suppressive alternatively activated macrophages, reduced IL-17A levels in the paw-draining LN, and protected joint morphology. Intravenous SA-IL-10 treatment showed similar efficacy as treatment with an anti-tumor necrosis factor antibody. SA-IL-10 was equally effective when administered intravenously, locally, or subcutaneously, which is a benefit for clinical translation of this molecule. CONCLUSION: SA fusion to IL-10 is a simple but effective engineering strategy for RA therapy and has potential for clinical translation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Yuba E, Budina E, Katsumata K, et al. Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models. Arthritis Rheumatol. 2021. PMID: 33169522. doi:10.1002/art.41585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。